News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium: The Takeda Oncology Company Pipeline Agents to be Featured at American Society of Hematology Annual Meeting


11/6/2012 7:44:55 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that more than 60 abstracts from studies involving five molecules in the Company’s portfolio have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 8 – 11 in Atlanta, Georgia. The abstracts include oral and poster presentations across a range of hematological diseases.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES